Drug intelligence / Profile preview

CTO-0101

Development stage: Phase 1
Lead developer: Taejoon Pharmaceutical
Administration: Ophthalmic

Overview

CTO-0101 is an investigational ophthalmic drug developed by Taejoon Pharm. It is being evaluated as an eye drop formulation in a Phase 1 clinical trial to assess its safety, tolerability, and pharmacokinetic characteristics in healthy adult volunteers. The specific mechanism of action and therapeutic target for CTO-0101 have not been disclosed publicly. As of the latest available information, the drug's highest development status is "Pending," with no approved indications or detailed mechanistic data released[1][2][4].

Beyond the preview

Go deeper on CTO-0101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTO-0101.

Explore the full profile